News and events
Read about the latest developments at NorthX Biologics and find out more about relevant happenings in the industry.
Leiden, The Netherlands - February 19, 2024 - Synerkine Pharma, a Dutch biopharmaceutical company creating innovative pain solutions, today announced a manufacturing alliance with NorthX Biologics AB, a leading biopharmaceutical company committed to pioneering solutions in gene therapy and biotechnology. The alliance will support Synerkine’s development portfolio, including its most advanced program SK-01, a cytokine-cytokine fusion protein combining the effects of IL-4 and IL-10 as a treatment option for chronic pain. SK-01 is progressing steadily toward clinical development with complex regional pain syndrome (CRPS), a severe chronic pain indication, as the lead indication.
In the dynamic and complex world of pharmaceuticals and drug development, the quest to find the right Contract Development and Manufacturing Organization (CDMO) often feels akin to searching for a life partner. As a person often facing and meeting the companies scouting for a CDMO I have heard this analogy so many times. This kind of partner hunt it's a journey filled with careful considerations, weighing options, and seeking that perfect match that aligns with your unique innovation needs. It is a in a way a “do we have the chemistry” test without pointing to the real type of chemistry. This intricate process, surprisingly like finding a soulmate, requires more than just a scientific approach - it's about understanding, compatibility, and a shared vision.
MATFORS, Sweden, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NorthX Biologics AB, a pioneer in biopharmaceutical innovation, is excited to announce the launch of its proprietary plasmids for the efficient manufacture of AAV (Adeno-Associated Virus) vectors for gene therapy. This strategic expansion complements NorthX's existing GMP and non-GMP plasmid and viral vector production capabilities, allowing the company to offer end-to-end support to gene therapy companies, from sequence design to the final release of AAV gene therapy product.
As the pharmaceutical and biotechnological industries are obliged to align their operations with Good Manufacturing Practice (GMP) guidelines, a unique set of challenges emerges for facilities tasked with producing non-GMP proteins. GMP is widely recognized as the gold standard for ensuring that products are consistently produced and controlled according to quality standards. However, in some cases, the production of non-GMP proteins (or “technical proteins), often required for research, industrial applications, or other non-clinical purposes, becomes a necessity. At NorthX we serve both the non-gmp and GMP protein communities and place a strong emphasis on utilizing a strong Quality Management System, while at the same time respecting the process for each product.
This article is written by NorthX Biologics Senior Advisor Helena Strigård och Bio-works Technologies CEO Jonathan Royce.
We will be attending BioProcessing 2023 and would love to meet. Contact us to book a meeting!
Celebrating its fifteenth year, The Bioprocessing Summit is a premier global forum for industry leaders to share the latest developments in bioprocess R&D, scale-up, quality and analytics. This year's programming comprises more in-depth content than ever before, showcasing 8 topic-focused streams, 14 conference tracks, interactive sessions, panel discussions, training seminars, research posters, and so much more.
Are you curious about how DNA plasmids are made? In this article, we guide you through the step-by-step process of constructing these essential genetic tools. We delve into the history and significance of DNA plasmids, as well as the necessary components and techniques involved in their preparation.
The initial phase in the production of cell-based therapies is where innovative ideas are explored and potential therapies are identified. In the dynamic and rapidly evolving field of cell therapy, thorough research and development play a vital role in bringing safe and effective treatments to patients.
DNA sequencing has opened up possibilities for research and medical treatments that were previously unimaginable. Thanks to it, we can improve our understanding of genetics and their role in living organisms, as well as decode genetic information to develop cures for diseases. In this article, we explore what DNA sequencing entails, from how it works to why it matters so much today.
Cell banking is the process of preserving cells for future use, typically for medical treatments or research purposes. It's a relatively new technology that has the potential to revolutionize healthcare. In this article, we explore what cell banking is, how it works, and why it's becoming increasingly important in the field of medicine. Whether you're a healthcare professional or simply curious about the latest advancements in science, this article provides you with a comprehensive understanding of this exciting new technology.
In the pharmaceutical and biotechnology industries, ensuring the safety, quality, and efficacy o products is of paramount importance. Good Manufacturing Practices provide a set of standards and guidelines that must be followed to maintain the integrity of the manufacturing process and guarantee the production of high-quality drugs.
Biologics solutions such as vaccines, gene therapies, and monoclonal antibodies, have revolutionized the pharmaceutical industry, offering innovative solutions for various diseases and conditions.However, with the growing number of biologics companies in the market, it can be overwhelming to narrow down your options and find the one that aligns with your specific needs.
In this article, we’ll guide you through the essential questions you should ask when searching for a biologics company. By asking the right questions, you can gain valuable insights and make an informed decision, ensuring that you collaborate with a company that meets your expectations and goals.
May 31- June 3rd, 2023
International Society for Cell and Gene Therapy (ISCT) Annual Meeting takes an integrative approach across all stakeholders to address key topics spanning translational research and preclinical development through to clinical trials, regulatory approvals, commercialization and ultimately patient access.
May 16 th - 20th.
The American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting is the premier event for professionals in gene and cell therapy.
Feb 28th - March 2nd.
Nu kan man läsa den spännande artikeln om innovationsfabriken på Dagens Industri.
We are proud to inform you that NorthX Biologics improved its score from bronze to silver in the International Sustainability Survey (EcoVadis) for year 2022!
CGTI leaders Summit 2023 February 15th 2023
Advanced Therapies Week is an event like no other!
Conference "Advanced Biologics in Matfors and Beyond" at NorthX Bio went to a big success!
Xintela och NorthX Biologics tillkännager att de har tecknat ett samarbetsramavtal för att gemensamt accelerera utveckling av avancerade terapier (ATMP) genom att tillvarata bolagens kompletterande kompetens och resurser inom ATMP-utveckling och GMP-tillverkning. Projekt som ska initieras inom ramen för samarbetet inkluderar bland annat produkt- och processutveckling, kvalitetsstyrning och utökad expansionskapacitet för tillverkning av ATMPer
The coming ATMP workshop will be host by NorthX Bio Matfors on the 14-15th December. Click on "Read more" to get the detailed program!
The world’s leading expo in the life sciences BIO-Europe will host its first in-person edition since 2019 in Leipziger Messe on 24 – 26 October.
Chetan is attending the Meeting on the Mesa event. Come and meet us !
NorthX Biologics (“NorthX”) styrelse har utsett Helena Strigård till ny vd. Hon kommer närmast från rollen som vd för branschorganisationen SwedenBIO. Helena kommer att leda NorthX fortsatta expansion av avancerad utveckling och produktion av biologiska läkemedel. Ted Fjällman, vd i NorthX och partner i huvudägaren Flerie Invest, fortsätter som ledamot i styrelsen.
MATFORS, Sweden, September 20, 2022 - The Board of NorthX Biologics ("NorthX") has appointed Helena Strigård as the new CEO. She joins NorthX from her role as Director General for the Swedish life science industry organization, SwedenBIO. Helena will lead NorthX's continued expansion in the development and production of advanced biologics. Ted Fjällman, current CEO of NorthX and Partner of the Company’s main investor, Flerie Invest, will continue to support the company as a member of the Board.
Please register to the seminar "Drug Development of Today and the Future" on the 19th of October!
New Horizons in Biologics & Bioprocessing, December 15th 2022
NorthX Biologics appoints industry veterans to its board of directors
Idag kan vi meddela att vi expanderar inom produktion av cellterapi bl.a. via partnerskap med Alder Therapeutics samt att vi expanderar med en andra tillverkningsanläggning på Karolinska.
2022-06-21
June 13-16, 2022・San Diego, CA
We are excited to be exhibiting at BIO USA this year. Come stop by our booth (#1054) or contact us to schedule a meeting.
"We welcome Dave Smith from Akron Bio and Ola Tuvesson from NorthX Biologics to present and discuss the critical functions of CMOs and their role in managing the challenges of adapting from traditional biologics to ATMPs."
Currently, mRNA medicines, such as vaccines, require freezers that can maintain −80 °C for large-scale handling and distribution. A new project has now started, with an aim to develop production processes for manufacturing mRNA medicines that remain stable even at 4 °C or higher. - The goal is to develop a dry vaccine, which would open up completely new opportunities for handling and distribution, says Randi Nordström, a researcher in formulation development at RISE.
Nordic Life Science Days (nlsd) is the largest Nordic partnering conference dedicated to the life science industry. The event attracts leading decision makers from biotech, pharma and med tech, as well as finance, research, policy and regulatory authorities.
The world tour is back! With more ’world leading’ activities within ATMP, highlighting and discussing the partnerships, infrastructures and competences critical to successes in our field.